North East and North Cumbria
ICS Formulary
ICS Formulary
5 Infections
05-03-03-02 Chronic hepatitis C & hepatitis D
| Daclatasvir |
|
Formulary
|
|
|
| Elbasvir & grazoprevir Zepatier® |
|
Formulary
|
|
 NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
|
|
| Glecaprevir & Pibrentasvir Maviret® |
|
Formulary
|
|
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
|
|
| Peginterferon Alfa Pegasys®, ViraferonPeg® |
|
Formulary
|
|
|
|
| Sofosbuvir Sovaldi® |
|
Formulary
|
|
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
|
|
| Sofosbuvir & Ledipasvir Harvoni® |
|
Formulary
|
|
|
NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
|
|
| Sofosbuvir & velpatasvir Epclusa® |
|
Formulary
|
|
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
|
|
| Sofosbuvir, Velpatasvir & Voxilaprevir Vosevi® |
|
Formulary
|
|
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
|
|
| Bulevirtide Hepcludex® |
|
Formulary
|
|
|
NICE TA896: Bulevirtide for treating chronic hepatitis D |
|
|
Links
- COVID-19 Therapeutic Alert
- Interim Clinical Commissioning Policy: Antivirals or neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients (Version 5 - effective from 10th February 2022)
- MHRA Drug Safety Update (Dec 2018): Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes
- MHRA Drug Safety Update (Jan 2017): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation
- MHRA Drug Safety Update (Jan 2017): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR
- MHRA Drug Safety Updates: Sofosbuvir and combinations - risk of severe bradycardia and heart block when taken with amiodarone
NENC ICB - Cellulitis Diagnosis and Management in Ambulatory Adults in primary care; Supporting Information- NICE NG15: Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
- NICE NG63: Antimicrobial stewardship: changing risk-related behaviours in the general population
- NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
- NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
- NICE TA252: Telaprevir in hepatitis C
- NICE TA330: Sofosbuvir for treating chronic hepatitis C
- NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
- NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
- NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
- NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
- NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
- NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
- NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
- NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
- NICE TA896: Bulevirtide for treating chronic hepatitis D
- NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
- North of Tyne, Gateshead and North Cumbria - Antibiotic and Diagnostic quick reference tools
- Primary Care Antimicrobial Guidelines
- TEWV: Antibiotic Prescribing Procedure
- UK Interim Clinical Commissioning Police - Therapies for patients with symptomatic hospital-onset COVID-19